You are here: Industry Insights > Catalent

News List

Catalent fills gap in the market with new development offering, Xpress Pharmaceutics CPhIonline
January 28, 2022
Xpress Pharmaceutics will facilitate adaptive clinical trials and reduce the time taken to complete FIH studies.
Catalent Completes Expansion of Advanced Containment Capabilities contractpharma
January 26, 2022
Expansion in large-scale isolator units at Malvern and Dartford, UK facilities to provide advanced containment capabilities for highly...
Catalent Launches New Xpress Pharmaceutics Service contractpharma
January 18, 2022
Expedites development of oral drugs for adaptive phase 1 clinical trials.
Catalent Increases Specialized Packaging Capabilities contractpharma
January 11, 2022
Expands Philadelphia facility to support growing biologic and cell and gene therapy markets.
BrainStorm, Catalent Complete Tech Transfer for NurOwn contractpharma
December 08, 2021
Autologous cell therapy for the treatment of ALS and PMS will be manufactured at Catalent’s 32,000 sq.-ft. cell therapy manufacturing facility in Houston.
Catalent embarks on $230M viral vector expansion project at Harmans campus CPhIonline
October 28, 2021
CDMO Catalent is to spend $230 million on adding three further commercial-scale viral vector manufacturing suites and associated support facilities and services at its gene therapy campus in Harmans, Maryland.
Catalent boosts nutraceuticals market presence with $1 billion Bettera acquisition cphi-online
September 23, 2021
The transaction is expected to accelerate Catalent's growth in global softgel and oral dose formulation and manufacturing services
Catalent, Edenbridge Pharma Enter Zydis Formulation Supply Agreement contractpharma
August 11, 2021
Novel formulation of glycopyrrolate will use Catalent’s Zydis ODT delivery technology for adjunctive therapy for the treatment of peptic ulcer.
Catalent Completes RheinCell Therapeutics Acquisition contractpharma
August 05, 2021
Catalent has completed the acquisition of RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs).
DisperSol signs up Catalent for manufacturing of multiple pharma products cphi-online
August 05, 2021
The collaboration will see Catalent install a commercial-scale KinetiSol technology manufacturing line at its Somerset, New Jersey, facility

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page